287 related articles for article (PubMed ID: 10470187)
21. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
22. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
24. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
25. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
[TBL] [Abstract][Full Text] [Related]
27. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
28. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
[TBL] [Abstract][Full Text] [Related]
29. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
30. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
31. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
32. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
34. Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A; Favier J; Hallensleben E; Burges A; Stieber P; de Bruijn HW; Fink D; Ferrero A; McGing P; Harlozinska A; Kainz Ch; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R; Goike H
Eur J Gynaecol Oncol; 2009; 30(6):609-15. PubMed ID: 20099488
[TBL] [Abstract][Full Text] [Related]
35. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
36. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
37. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
38. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
39. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
40. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
